FindTrial
Sign In

INCB024360

DRUG5 trials

Sponsors

Incyte Corporation, H. Lee Moffitt Cancer Center and Research Institute, Masonic Cancer Center, University of Minnesota

Conditions

Bladder CancerEndometrial CancerFallopian Tube CarcinomaGastric CancerHead and Neck CancerHepatocellular Carcinoma (HCC)Lung CancerLymphoma

Phase 1

A Dose-escalation Study in Subjects With Advanced Malignancies
CompletedNCT01195311
Incyte CorporationSolid Tumors and Hematologic Malignancy
Start: 2010-07-31End: 2013-07-31Updated: 2018-01-17
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
CompletedNCT02118285
Masonic Cancer Center, University of MinnesotaFallopian Tube Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma
Start: 2014-07-28End: 2015-11-12Updated: 2017-12-05
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
CompletedNCT02178722
Incyte CorporationBladder Cancer, Endometrial Cancer, Gastric Cancer +11
Start: 2014-07-17End: 2020-11-06Updated: 2022-02-14
A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
CompletedNCT02318277
Incyte CorporationHead and Neck Cancer, Lung Cancer, Solid Tumors +1
Start: 2015-01-05End: 2020-10-16Updated: 2022-01-13

Phase 2

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)
CompletedNCT01822691
H. Lee Moffitt Cancer Center and Research InstituteMyelodysplastic Syndromes
Start: 2013-07-31End: 2015-02-28Updated: 2016-01-18

Related Papers

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
BMC Cancer2024-07-2513 citations
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
BMC Cancer2024-07-259 citations
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.
2024-07-256 citations
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.
2024-07-255 citations
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
Cancer2022-10-3017 citations
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
Regular and Young Investigator Award Abstracts2020-11-0117 citations
Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
Cancer Research2018-07-0125 citations
Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.
Journal of Clinical Oncology2018-05-208 citations
Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.
Journal of Clinical Oncology2018-05-207 citations
Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology2017-05-2068 citations
Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology2017-05-2067 citations
Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology2017-05-2067 citations
Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology2017-05-2053 citations
Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.
Journal of Clinical Oncology2017-05-2044 citations
Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.
Journal of Clinical Oncology2017-05-2035 citations
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
Blood2014-12-067 citations